Aurobindo Pharma Subsidiary Launches Generic Advair Diskus in US

Aurobindo Pharma announced that its wholly owned subsidiary, Lannett Company LLC, has launched the generic equivalent of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in the US market. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in the US. The product is available in 100/50 mcg and 250/50 mcg strengths and is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This launch signifies Aurobindo's strategic focus on expanding its complex and differentiated inhalation product portfolio.